BCATc Inhibitor 2

BCATc Inhibitor 2 is a selective branched-chain aminotransferase (BCAT) inhibitor for research of neurodegenerative diseases. The IC50s of 0.2 μM, 0.8 μM and 3.0 μM for rat cytosolic isoenzyme rBCATc, human cytosolic isoenzyme hBCATc and rat mitochondrial isoenzyme rBCATm, respectively[1].

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

IC50: 0.2 μM (rBCATc), 0.8 μM (hBCATc), 3.0 μM (rBCATm)[1].

BCATc Inhibitor 2 decreases calcium influx in neuronal cultures with an IC50=4.8±1.2 μM[1].

BCATc Inhibitor 2 also blocks calcium influx into neuronal cells following inhibition of glutamate uptake, and demonstrates neuroprotective efficacy in vivo[1]. Following a 30 mg/kg subcutaneous injection to Lewis rats, BCATc Inhibitor 2 reaches a peak plasma concentration (Cmax) of 8.28 μg/mL at 0.5 h (tmax). The mean plasma exposure (AUC) value is 19.9 μg h/mL, and the mean terminal half-life ranged from 12 to 15 h, indicating favorable PK parameters of BCATc Inhibitor 2[1].

[1]. Lain-Yen Hu, et al. The Design and Synthesis of Human Branched-Chain Amino Acid Aminotransferase Inhibitors for Treatment of Neurodegenerative Diseases. Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40.